Cautions and reporting a problem | California peptide treatment

Pause at a research label

Stop and ask about a product labelled “research use only” before using it as medicine.

In its warnings, the US Food and Drug Administration (FDA) called some products bearing this label unapproved medicines.

Those warning letters were checked September 26, 2026.

Federal law prohibits giving out prescription-only drugs without a valid prescription (checked September 26, 2026).

Pause if a service offers to skip the prescription.

For a patient, compounding involves a doctor or pharmacist preparing a medicine by making or mixing it.

Poor compounding can put germs into a medicine or give it the wrong amount of active ingredient—the part that makes it work.

Semaglutide is an ingredient in some diabetes and weight-loss medicines.

The FDA has reports of hospital care following possible errors in how much compounded semaglutide people injected.

The FDA reported these problems; that warning was checked September 26, 2026.

Ask the person who prescribed the medicine, or your pharmacist, to explain the directions before you use it.

Each product has its own storage needs: some peptide medicines require cooling, and others can stay at room temperature.

Use the product label and pharmacist’s instructions to check storage.

Patients can tell the FDA directly about a medicine problem through MedWatch, without paying a fee.

An FDA report does not by itself show that a drug caused the problem.

For a California complaint, match the person or pharmacy to its board.